INTRODUCTION
In recent years, studies have shown an inverse relationship between testosterone with metabolic syndrome as well as T2DM (1) . Testosterone has been found to play a significant role in obesity, glucose homeostasis, and lipid metabolism. Cross-sectional epidemiological studies have reported a direct correlation between plasma testosterone and insulin sensitivity (2) , and low testosterone levels have been associated with an increased risk of T2DM, which has been illustrated by androgen deprivation in men with prostate carcinoma (3) . Several studies have suggested that men with low testosterone are at a greater risk of developing T2DM and may even predict the onset of diabetes (4) (5) (6) (7) (8) . A systematic review of 43 studies including 6427 men by Ding, et al suggested that higher plasma levels of testosterone were associated with lower risk of T2DM and vice versa (9) . Similarly, Haffner et al demonstrated that low sex hormone-binding globulin (SHBG) and testosterone levels are associated with higher glucose and insulin levels and increased obesity (8) . Osuna et al correlated waist circumference, body mass index (BMI), insulin, and homeostatic model assessment of insulin resistance (HOMA-IR) to testosterone levels and, in each case, found a significant negative correlation with all these parameters (10) . These findings when taken together, raise the possibility that testosterone may be having a protective function against the development of diabetes mellitus in men.
Testosterone replacement has been found to reverse some parts of the unfavourable risk profile for the development of diabetes mellitus and atherosclerosis in hypogonadal males (11) . Fukui et al demonstrated that serum testosterone levels are lower in a large number of Japanese patients with T2DM when compared with healthy men and testosterone supplementation could decrease insulin resistance (IR) and atherosclerosis in these hypogonadal males (12) . Boyanov et al also showed that men with T2DM receiving three months of testosterone supplementation had decreased fasting glucose, postprandial glucose, mean daily glucose and HbA1c values, compared with baseline in men with T2DM (13 testosterone treatment in insulin-dependent hypogonadal patients improved the glycaemic control and reduced their insulin dosages by a mean of seven units (14) . Naharci et al also had demonstrated that long term testosterone therapy can improve the insulin sensitivity and body composition parameters, especially the body fat mass (15) .
METHODS
A detailed history, clinical examination and investigations were done in each patient in order to assess disease severity, its microvascular complications and severity of hypogonadism. History taking included symptoms of neuropathy, past history of hypertension and use of anti-hypertensive medications. The ADAM (Androgen Deprivation in Ageing Male) questionnaire ( Table 1) .was used to score the severity of hypogonadism. Diabetic neuropathy was deemed to be present if the patient complained of any symptom of neuropathy after ruling out other disorders that can cause neuropathy on the basis of history and clinical examination. Examination of deep tendon reflexes, 10g monofilament test, vibration and proprioception sense were used to find out the presence of neuropathy. Indirect ophthalmoscopy was used to screen diabetic retinopathy. Non-hypertensive patients with diabetes mellitus were screened for nephropathy with urine microalbumin test and heat coagulation tests. Serum testosterone levels (morning sample) were estimated using chemiluminescence immunoassay. Low testosterone was defined as serum total testosterone level <241ng/dl and the prevalence of its deficiency was calculated. Informed consent was taken from all the participants in the study. If you answer 'yes' to number 1 or 7 or if you answer 'yes' to more than 3 questions , you may have low testosterone.
Many male patients with T2DM are likely to have evidence of hypogonadism at the time of diagnosis, which has an important bearing on the disease pathogenesis as well as the quality of life of the individual. However, the implications of low testosterone levels of these men on complications of diabetes are largely unknown. The objective of this study was to assess the testosterone levels in newly diagnosed male patients with T2DM and to assess any correlation with microvascular complications.
This case-control study was conducted on 168 subjects at MLN Medical College, Allahabad and its associated SRN Hospital, Allahabad from March 2013 to July 2014. 168 male subjects between 18-60 years of age were recruited for the study. Of these 168 subjects, 83 were T2DM who were diagnosed during the last 3 months, according to the 2012 American Diabetes Association guidelines and were considered as study subjects, either admitted to SRN Hospital or attending Medicine OPD. Rest of the 85 individuals were age and BMI matched non-diabetic healthy male volunteers who were considered for the control group. Patients with type 1 diabetes mellitus, those who were on hormone replacement therapy (steroids or testosterone), patients with chronic renal or hepatic disease, HIV infection, surgically uncorrected cryptorchidism, malignancy and the patients who were on chemotherapeutic agents or radiation therapy, prior infectious orchitis and those in whom surgical orchiectomy was done, were excluded from the study.
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The response to ADAM questionnaire was more frequently positive in patients with low testosterone levels (89.2%; p<0.0001) compared to study patients with normal testosterone levels ( Table 4) . Microvascular complications were more prevalent among the study patients with low testosterone levels compared to the study patients with normal testosterone levels (p<0.0001) as depicted in Table 5 .
DISCUSSION

RESULTS
Testosterone deficiency is more prevalent in newly diagnosed T2DM patients compared to non-diabetic patients. More positive results with ADAM questionnaire were found in patients with low testosterone. In patients with diabetes, low testosterone levels seem to have positive correlation with the incidence of microvascular complications of diabetes.
Serum testosterone level tends to decline with age by approximately 0.5-2% per year which seems to be a normal aging process of men. This observation has been confirmed by several previous studies (6, 16, 17, 18, 19) . Low testosterone levels are common in patients with T2DM. Hayek et al. found that 36.5% of patients with T2DM had testosterone levels <300 ng/dl and 29% had symptoms of androgen deficiency (20) . Kapoor et al. showed that 20% of men with diabetes have testosterone levels <230 ng/dl and 31% have levels between 230-346 ng/dl (20) . Grossman et al have shown similar results where 43% of men with T2DM had low testosterone levels (<288 ng/dl), which increased up to 61% in men who were 80 years or older (22) . Table 2 shows distribution of serum testosterone deficiency among cases and controls. Lower testosterone levels were observed at a younger age in patients with diabetes compared to non-diabetic healthy volunteers ( Table 2 ).
Out of the 83 patients of T2DM, low serum testosterone levels were found in 37(44.58%) while low levels were present only in 10(11.8%) of 85 controls, which was found to be statistically significant (χ2 = 20.84, df =1, p<0.0001) ( Table 3 ). The mean serum testosterone levels in study subjects were significantly lower compared to control group (254.99±154.15 ng/dl vs. 360.66±120.74 ng/dl, CI 95%, t =4.9529, df =166, p<0.0001).
Testosterone biosynthesis is regulated primarily by pulsatile secretion of LH and the serum levels reflect the integrity of the hypothalamic-pituitary-gonadal (HPG) axis. Low testosterone levels noted in cases of insulin resistance may indicate a defect at one or more functional levels of the HPG axis. In a background of insulin-resistance, Leydig cell function, particularly steroidogenesis, may be impaired by changes in the production of hormones and
The relationship between serum testosterone levels and microvascular complications of diabetes mellitus was evaluated. Continuous variables were compared using 't' test for independent variables and Chi-square test was applied on categorical variables.
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cytokines locally in the target tissue and in adipose tissue. Although the studies suggest that increasing insulin resistance may be attributed to a decrease in testosterone secretion in men, it is not fully clear as to how the HPG axis mediates the interplay between testosterone and insulin levels. Other potential mechanisms for low testosterone levels in T2DM include reduced or absent stimulatory effect of insulin on Leydig cells and Leydig cell dysfunction and steroid biosynthesis inhibition by increase leptin and TNF levels. Diabetes mellitus is strongly associated with microvascular complications such as neuropathy, retinopathy and nephropathy resulting in organ and tissue damage and these complications are seen in approximately one-third to one-half of people with the disease (23) . There has been a significant correlation between the microvascular complications and the testosterone level of these patients and this association has been strongest with diabetic neuropathy (12, 22, 24) . This study also demonstrated a significant correlation with low Prevalence of hypogonadism is significantly higher in newly diagnosed T2DM patients compared to controls.
CONCLUSIONS
serum testosterone levels and the presence of diabetes related microvascular complications (neuropathy in 59.46%, retinopathy in 27% and nephropathy in 21.62%) with a stronger association with diabetic neuropathy.
The ADAM questionnaire was positive more frequently in patients with low testosterone levels (89.2%) and this difference was statistically significant (P<0.0001). This suggests that majority of males with newly diagnosed T2DM had evidence of symptomatic hypogonadism at the time of diagnosis. Using the definition of hypogonadism as the combination of symptoms (positive ADAM score) in addition to a low testosterone level, Kapoor et al demonstrated that 17% of the patients with T2DM have overt hypogonadism with a total testosterone<230 ng/dl and 25% patients have possible hypogonadism with total testosterone between 230-346 ng/dl (21).
The main strength of this study is its matched casecontrol design, which is controlled for age and BMI by design and analysis that minimized the bias due to confounders. However, cross sectional design made it difficult to determine whether diabetes was preceded or followed by the decline in serum testosterone levels. This effect was minimized by recruiting newly diagnosed patients with diabetes. Due to the effect of circadian rhythm, the pulsatile nature of its secretion, use of concomitant medications and measurement variations, the testosterone level can vary and a single testosterone value could have been inadequate for making a diagnosis of hypogonadism. Free testosterone values are known to represent the actual evidence of hypogonadism. Due to the inaccuracy of conventional methods in assessing free testosterone levels, free levels were not estimated and had to rely on total testosterone levels. Furthermore, the cross sectional design limits the ability to assess causality. Due to the time constraints and the stringent selection criteria, the sample size was small and generalization of the results was a problem.
Subjective evidence of hypogonadism using ADAM questionnaire is seen more commonly in patients with low testosterone compared to those with normal levels.
